ReviewAdvances in therapy2016
Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration.
Review in Advances in therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03408756 (A Randomized Controlled Trial Comparing the Efficacy and Safety Profile of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis), which is not on this map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Controlled Trial Comparing the Efficacy and Safety Profile of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A meta-analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitis.British journal of clinical pharmacology · 2023Pooled it
- Attitudes of healthcare professionals towards the use of parenteral methotrexate in rheumatoid arthritis patients: a qualitative study.International journal of clinical pharmacy · 2026Article
- Real-world epidemiology and management of patients with rheumatoid arthritis treated with methotrexate in France: a decade after methotrexate first recommendations.EULAR rheumatology open · 2026Article
- Perspectives of patients with rheumatoid arthritis towards the use of parenteral methotrexate: a qualitative study.International journal of clinical pharmacy · 2026Article
- Drivers of Methotrexate Polyglutamate Concentration in Erythrocytes: Insights from Immune-Mediated Inflammatory Diseases and Pediatric Acute Lymphoblastic Leukemia.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Efficacy and Safety of Rapid Dose Escalation of Methotrexate in Rheumatoid Arthritis (Results of the Multicenter METEOR Study).Doklady. Biochemistry and biophysics · 2026Article
- Oral administration of probiotic colony-like micro-nano system for immunoregulation of rheumatoid arthritis.Acta pharmaceutica Sinica. B · 2026Article
- Comprehensive Literature Review Evaluating the Use, Safety, and Efficacy of Subcutaneous Methotrexate in the Treatment of Adult Patients With Moderate-To-Severe Plaque-Type Psoriasis.International journal of dermatology · 2025Review
- Tacrolimus and diabetic rodent models.Pharmacological reports : PR · 2025Review
- Acute Kidney Injury in Autoimmune-Mediated Rheumatic Diseases.Journal of clinical medicine research · 2025Review
- Molecular mechanisms underlying methotrexate-induced intestinal injury and protective strategies.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Appraisal of anti-inflammatory and immunomodulatory potential of ramipril against Freund's adjuvant-provoked arthritic rat model.Inflammopharmacology · 2023Article
- Effects of Subcutaneous Methotrexate in Patients with Refractory Uveitis and Chorioretinitis.Korean journal of ophthalmology : KJO · 2023Article
- The Utility of Peptide Ligand-Functionalized Liposomes for Subcutaneous Drug Delivery for Arthritis Therapy.International journal of molecular sciences · 2023Article
- Methotrexate as a corticosteroid-sparing agent in leprosy reactions: A French multicenter retrospective study.PLoS neglected tropical diseases · 2023Article
- Clinical Factors and the Outcome of Treatment with Methotrexate in Rheumatoid Arthritis: Role of Rheumatoid Factor, Erosive Disease and High Level of Erythrocyte Sedimentation Rate.Journal of clinical medicine · 2022Article
- Therapeutic Maintenance Level of Methotrexate in Rheumatoid Arthritis: A RBSMR Study.Mediterranean journal of rheumatology · 2022Article
- Differences in Administration of Methotrexate and Impact on Outcome in Low-Risk Gestational Trophoblastic Neoplasia.Cancers · 2022Article
- High Efficacy Combined Microneedles Array with Methotrexate Nanocrystals for Effective Anti-Rheumatoid Arthritis.International journal of nanomedicine · 2022Article
- Construction of a Nano-Controlled Release Methotrexate Delivery System for the Treatment of Rheumatoid Arthritis by Local Percutaneous Administration.Nanomaterials (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledMethotrexate (MTX) is still considered the drug of choice in rheumatoid arthritis (RA) management. Comparing subcutaneous (MTX SC) and oral (MTX OR) routes of administration is important to optimize the everyday therapeutic strategy in the real-life setting. This review summarizes scientific evidence currently available on this topic. As shown by pharmacokinetic studies, at the same dose level, bioavailability of MTX SC is significantly higher and less variable than that of MTX OR. This difference is even more pronounced for medium-to-high dosages (i.e., >15 mg/week). With regard to clinical response (Disease Activity Score-28, American College of Rheumatology Criteria), randomized, double-blind studies and retrospective or longitudinal analyses in real-life settings showed that MTX SC is more effective than MTX OR. This is true both in MTX-naive patients with early RA, and in patients who switch from MTX OR to MTX SC due to previous treatment failure, lack of efficacy and/or adverse events. Finally, MTX SC has a better tolerability profile than MTX OR, with fewer gastroenterological side effects. Delaying the use of more expensive biological therapies by switching from MTX OR to MTX SC in non-responders might provide cost savings, with relevant implications in the management of patients with RA.
fundingAlfa Wassermann.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.